FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors

DIVISLAB

3,542.35
-3.95 (-0.11%)
Updated 03:29 24/11 IST

DIVISLAB Buy or Sell - FrontPage Forums

3 Users have submitted 3 trade ideas of Rs. 49,479.75 for DIVISLAB
Disclaimer
100% Bullish
0% Bearish

DIVISLAB Buy or Sell - Brokerage Reports

No. of reports in last year
4
No. of analysts
3
Average Consensus Forecast
2828.25
Consensus Potential
-32.47%
See DIVISLAB Share Price Targets >>

DIVISLAB Ratings

Long term DIVISLAB rating by FrontPage users
4/5 (2 Ratings)
Find answers to all your questions on live DIVISLAB message board: Is DIVISLAB buy or sell? Should I buy DIVISLAB shares? Why are DIVISLAB shares falling? Should I invest in DIVISLAB stock?

  1. Home
  2. DIVISLAB Forum

DIVISLAB Share Price Discussion

N
Reputation: 8,046 • Yesterday 8:08 AM
Sensex seen at 45,500; these 5 stocks gave positive surprise with Q2 earnings: ICICI Direct
Post Q2FY21, ICICI Direct marginally revised its FY21-22 estimates and introduce FY23 estimated numbers. Going forward, it expects Nifty earnings to grow at 17.5 percent CAGR in FY20-23.
Moneycontrol
Like
Reply

Type
Buy
Instrument
NIFTY 26NOV20 13100 CE
Entry Price
₹54.7
Price@Trade
₹54.7
Target Price
₹72
Stop Price
₹43
Valid Till
Nov 24, 2020 3:20 AM
Margin
₹410,250 approx for 7500 Qty
Status
Active
Like
Reply

Type
Buy
Instrument
BALKRISIND NOV20 1700 PE
Entry Price
₹34.95
Price@Trade
₹34.95
Target Price
₹47
Stop Price
₹34.9
Valid Till
Nov 25, 2020 3:20 AM
Margin
₹838,800 approx for 24000 Qty
Status
Active
Like
Reply

Type
Sell
Instrument
NIFTY 26NOV20 12800 CE
Entry Price
₹275
Price@Trade
₹275
Target Price
₹250
Stop Price
₹300
Valid Till
Nov 24, 2020 3:20 AM
Margin
₹158,819 approx for 75 Qty
Status
Active
Like
Reply

Type
Buy
Instrument
NIFTY 26NOV20 13100 PE
Entry Price
₹93.2
Price@Trade
₹93.2
Target Price
₹300
Stop Price
₹50
Valid Till
Nov 26, 2020 3:20 AM
Margin
₹34,950 approx for 375 Qty
Status
Active
Like
Reply

Type
Buy
Instrument
BANKNIFTY 26NOV20 30000 CE
Entry Price
₹176
Price@Trade
₹179.7
Target Price
₹250
Stop Price
₹150
Valid Till
Nov 26, 2020 3:20 AM
Margin
₹88,000 approx for 500 Qty
Status
Waiting for entry
Like
Reply
M
Reputation: 292 • Yesterday 8:07 AM

Type
Buy
Instrument
SORILINFRA
Entry Price
₹69.6
Price@Trade
₹69.6
Target Price
₹80
Stop Price
₹65
Valid Till
Dec 24, 2020 3:20 AM
Margin
₹6,960 approx for 100 Qty
Status
Active
Like
Reply
R
Reputation: 1,101 • Yesterday 8:06 AM
Riyaan in NIFTY-BANK
29900CE 26th NOV AT 200/205 TARGET 230/270 #NIF...
Like
Reply

Type
Sell
Instrument
HDFC
Entry Price
₹2,233  2233.0
Price@Trade
₹2,231.85
Target Price
₹2,150
Stop Price
₹2,300
Valid Till
Dec 2, 2020 3:20 AM
Margin
₹24,563 approx for 11 Qty
Status
Active
Like
Reply (3)
See all replies
MAHESH MAKWANA @maheshmakwana
Yesterday 8:07 AM

Update
Entry Price Modified
Price @ Update
₹2,230.25
Original Entry Price
₹2,233
New Entry Price
2231.0
MAHESH MAKWANA @maheshmakwana
Yesterday 8:07 AM

Update
Entry Price Modified
Price @ Update
₹2,231.85
Original Entry Price
₹2,231
New Entry Price
2233.0
TrackerBot @trackerbot
Yesterday 8:07 AM

Update
Trade Entered
Entry Price
2233.0

Type
Sell
Instrument
BANKNIFTY 26NOV20 FUT
Entry Price
₹29,690
Price@Trade
₹29,690
Target Price
₹29,600
Stop Price
₹29,770
Valid Till
Nov 24, 2020 3:20 AM
Margin
₹156,379 approx for 25 Qty
Status
Active
Like
Reply
B
Reputation: 17,813 • Yesterday 8:06 AM

Type
Sell
Instrument
BANKNIFTY 26NOV20 29800 CE
Entry Price
₹275
Price@Trade
₹269.05
Target Price
₹100
Stop Price
₹310
Valid Till
Nov 26, 2020 3:20 AM
Margin
₹1,223,426 approx for 225 Qty
Status
Active
Like
Reply (1)
See all replies
TrackerBot @trackerbot
Yesterday 8:07 AM

Update
Trade Entered
Entry Price
₹275

Type
Buy
Instrument
BANKNIFTY 26NOV20 29700 CE
Entry Price
₹324
Price@Trade
₹324
Target Price
₹6,000
Stop Price
₹100
Valid Till
Nov 24, 2020 3:20 AM
Margin
₹648,000 approx for 2000 Qty
Status
Active
Like
Reply

Type
Buy
Instrument
IEX
Entry Price
₹212.25
Price@Trade
₹212.25
Target Price
₹225
Stop Price
₹200
Valid Till
Nov 25, 2020 3:20 AM
Margin
₹212.25 approx for 1 Qty
Status
Active
Like
Reply
Pyramidstock in HDFCBANK
buy hdfcbank cmp 1419 sl 1405 tgt 1430-1440 int...
Like
Reply

BUY 29600 CE ABOVE 360
TARGET 25/60/120
SL 35
Like
Reply

Type
Buy
Instrument
COROMANDEL
Entry Price
₹806.7
Price@Trade
₹805.75
Target Price
₹840
Stop Price
₹785
Valid Till
Nov 25, 2020 3:20 AM
Margin
₹806.7 approx for 1 Qty
Status
Active
Like
Reply (1)
See all replies
TrackerBot @trackerbot
Yesterday 8:06 AM

Update
Trade Entered
Entry Price
₹806.7
Like
Reply
M
Reputation: -27,999 • Yesterday 8:04 AM

Type
Buy
Instrument
BANKNIFTY 26NOV20 29800 CE
Entry Price
₹285
Price@Trade
₹259.05
Target Price
₹400
Stop Price
₹200
Valid Till
Nov 26, 2020 3:20 AM
Margin
₹7,125 approx for 25 Qty
Status
Waiting for entry
Like
Reply

Type
Buy
Instrument
IEX
Entry Price
₹212.5
Price@Trade
₹212.3
Target Price
₹225
Stop Price
₹200
Valid Till
Nov 24, 2020 3:20 AM
Margin
₹212.5 approx for 1 Qty
Status
Active
Like
Reply (1)
See all replies
TrackerBot @trackerbot
Yesterday 8:06 AM

Update
Trade Entered
Entry Price
₹212.5
S
Reputation: -10,960 • Yesterday 8:04 AM

Type
Buy
Instrument
BANKNIFTY 26NOV20 32000 CE
Entry Price
₹4.5
Price@Trade
₹4.45
Target Price
₹10
Stop Price
₹1
Valid Till
Nov 26, 2020 3:20 AM
Margin
₹112,500 approx for 25000 Qty
Status
Active
Like
Reply (1)
See all replies
TrackerBot @trackerbot
Yesterday 8:06 AM

Update
Trade Entered
Entry Price
₹4.5
Join FrontPage
FrontPage is India's favorite stock discussions community
Join 50,000 Indian traders and discuss trades, strategies, news & views on any stock.
  • DIVISLAB - Share Price - Fundamentals

    keyboard_arrow_down
    Market Capitalization45,211.44
    Enterprise Value45,212.24
    Price to Earnings33.24
    Price to Book Value6.48
    Return on Capital Employed0.2
    Return on Equity0.15
    Face Value2
    Dividend Yield0.01
  • DIVISLAB - Brokerage Reports

    keyboard_arrow_down
    DateBrokerageCallTarget
    8-Nov-20Motilal OswalBuy3,900
    12-Aug-20Karvy Stock BrokingSell2,912
    8-Jun-20Karvy Stock BrokingSell2,071
    20-Feb-20SharekhanBuy2,430
    19-Aug-19SharekhanBuy1,800
    DIVISLAB Brokerage Price Target
  • DIVISLAB Share Price - Historical (₹)

    keyboard_arrow_down
    DateOpenHighLowClose
    Nov 243609.953609.9534933537.05
    Nov 233486.43637.83470.53546.3
    Nov 203442349034253469.1
    Nov 19343634993406.33435.05
    Nov 18344034623410.43451.8
  • DIVISLAB Share Price - Daily Moving Averages (DMA)

    keyboard_arrow_down
    20 Day Moving Average₹3,296.28
    30 Day Moving Average₹3,238.57
    50 Day Moving Average₹3,203.23
    100 Day Moving Average₹2,965.36
    200 Day Moving Average₹2,586.3
  • DIVISLAB - Profit And Loss

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Revenue3,8164,023.47-0.05
    Operating Profit1,2521,438.85-0.13
    Profit Before Tax1,2191,388.23-0.12
    Net Income8701,053.27-0.17
  • DIVISLAB - Balance Sheet

    keyboard_arrow_down
    CONSOLIDATEDMar-19Mar-18 % Change
    Shareholder's Funds6,9735,9600.17
    Total Liabilities1,0678610.24
    Total Assets8,0406,8210.18
  • DIVISLAB - Cash Flow

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Cash from Operating Activity7651,148.05-0.33
    Cash from Investing Activity-476-1,134.08-0.58
    Cash from Financing Activity-314-9.3132.73
    Net Cash Flow-254.66-6.36
  • DIVISLAB - Ratios

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17
    Return on Assets0.130.17
    Return on Equity0.150.19
    Return on Capital Employed0.20.26
  • DIVISLAB - 3 year Growth

    keyboard_arrow_down
    3 Year CAGR Growth in Revenue0.24
    3 Year CAGR Growth in Operating Profit0.08
    3 Year CAGR Growth in EBIDTA0.13
    3 Year CAGR Growth in Net Income0.03
    3 Yr CAGR Growth - Diluted EPS-0.49
  • DIVISLAB - 5 year Growth

    keyboard_arrow_down
    5 Year CAGR Growth in Revenue0.79
    5 Year CAGR Growth in Operating Profit0.52
    5 Year CAGR Growth in EBIDTA0.57
    5 Year CAGR Growth in Net Income0.42
    3 Yr CAGR Growth - Diluted EPS-0.29
  • DIVISLAB - Recent News

    keyboard_arrow_down
    NewsBot
    Yesterday 8:08 AM
    Sensex seen at 45,500; these 5 stocks gave positive surprise with Q2 earnings: ICICI Direct
    Moneycontrol
    NewsBot
    Nov 11 5:13 AM
    Buy Divis Laboratories: target of Rs 3800: Sharekhan
    Moneycontrol
    NewsBot
    Nov 10 5:48 AM
    Buy Divi’s Laboratories; target of Rs 3900: Motilal Oswal
    Moneycontrol
    NewsBot
    Nov 9 7:23 AM
    Accumulate Divi's Laboratories; target of Rs 3515: Dolat Capital Market
    Moneycontrol
    NewsBot
    Nov 9 5:33 AM
    Buy Divi's Laboratories; target of Rs 4205: ICICI Direct
    Moneycontrol
    NewsBot
    Nov 9 3:33 AM
    Divis Labs share price hits 52-week high after Q2 profit jumps 45%
    Moneycontrol
    NewsBot
    Nov 7 10:13 AM
    Divi's Laboratories Q2 net profit up 46% at Rs 520 crore
    Moneycontrol
    NewsBot
    Aug 20 2:28 AM
    SBI Life, Divis Labs to replace Bharti Infratel, ZEE in Nifty50
    Moneycontrol
    NewsBot
    Aug 11 12:43 PM
    Buy Divi’s Laboratories; target of Rs 3350: Motilal Oswal
    Moneycontrol
    NewsBot
    Aug 11 12:43 PM
    Buy Divis Laboratories; target of Rs 3400: Sharekhan
    Moneycontrol
  • DIVISLAB - Related Communities

    keyboard_arrow_down
    Sun Pharmaceutical Industries Ltd. NS...
    Cipla Ltd. NSE: CIPLA | BSE: 500087 |...
    Aurobindo Pharma Ltd. NSE: AUROPHARMA...
    Biocon Ltd. NSE: BIOCON | BSE: 532523...
    Lupin Ltd. NSE: LUPIN | BSE: 500257 |...
    Dr. Reddy's Laboratories Ltd. NSE: DR...
    Glenmark Pharmaceuticals Ltd. NSE: GL...
    Piramal Enterprises Ltd. NSE: PEL | B...
    Apollo Hospitals Enterprise Ltd. NSE:...
    Cadila Healthcare Ltd. NSE: CADILAHC ...
  • DIVISLAB - More Information

    keyboard_arrow_down

    Divi's Laboratories Ltd:
    Divi's Laboratories Limited is incorporated back in 1990 and headquartered in Hyderabad, Telangana, India. This company, at its initial stage of the foundation, was named as Divi's Research Centre and later on in 1994 was changed to Divi's Laboratories Limited. This company is responsible for manufacturing and selling APIs or active pharmaceutical ingredients along with intermediates for generics. This is carried on in India, other parts of Asia, US, Europe and several other parts of the world.
    It offers the different unit for building compounds like several carotenoids inclusive of beta-carotene, astaxanthin, canthaxanthin, lycopene, and apocarotenol. Other than this it also offers groups for building protects amino acids like FMOC, BCZ and BOC as well as for chiral ligands and peptide and nucleotides.
    Apart from this, it also customizes the synthesis of several active pharmaceutical ingredients along with advanced forms of discovered compounds for other pharmaceutical companies. It also offers full-time contract-based research on development processes to identify new compounds.
    Company Information:
    Between the years 1991-1993, Divi's developed multiple bulk actives and other intermediates products for several other manufacturing companies. It received its ISO-9002 certification with compliance to SGS-Yarsley belonging to the UK, back in 1997. With the following two years, in 1999, the company received a Certificate of Suitability from the European Directorate for the production of Naproxen.
    For the company's system of occupational health and safety management, it received the OHSAS-18001 certificate. It was given to them by BVQI from London in 2001. In the year 2002, Divi's set up their Unit number II, a manufacturing facility in Chippada. In the following year in 2003, the company inaugurated a new research centre in Vizag, named DRC-Vizag. This was built for fundamental research in specific core segments.
    In the year 2004, Rs 3035.21 lakh was invested by Divi's for adding machines to both of their units in Unit-I (Choutuppal) and Unit-II (Chippada), and this was accounted for in their capital expenditure. In 2006, it received an approval letter from the Ministry of Commerce in India. This was for setting up a Special Economic Zone for multiple pharma based ingredients at Chippada, Vizag which led the company to invest Rs 200 crore.
    During the year 2008-09, the company's portfolio added a total of 9 products. Four of these nine products consisted of generic APIs, and the rest belonged to intermediates and custom synthesis of APIs. Another seven products were added to the company portfolio in 2009-2010. Out of these seven products, 2 were generic APIs along with intermediates, while the rests were intermediates and custom synthesis APIs. During the year 2012-13, the company went on to add another nine products out of which three of these were generic APIs along with intermediates, and the rest six were custom synthesis APIs and intermediates.
    On 19 February 2016, the company went through an inspection by US-FDA for its second unit in Chapada, Bhemunipatam near Vizag and was this event was successful which happened without any observation. In 2017, on 18 November, the company announced that it had received EIR (Establishment Inspection Report) from FDA (US) for their second unit in Vizag. On 16 May 2018, Divi's Laboratories stated that their Unit-I in Telangana was under the inspection of the US-FDA starting from 14 May 2018 to 16 May 2018. The review conducted was a cGMP general inspection done by the FDA.
    The company is one of the biggest pharmaceutical companies in the country, which currently has a portfolio of 120 products. It has presently products belonging to multiple therapeutic aspects. It has a total of four manufacturing units with a developing market presence in several countries. Their first facility is located in Yadadri Bhuvanagiri District; Telangana consists of 11 blocks for multipurpose production along with finishes product spaces for APIs.
    How Divi’s Laboratories, is categorised as a Pharmaceutical and Health care Sector, and Pharmaceutical Industry :
    The Pharmaceutical Industry includes companies that derive their business by researching, discovering, developing, manufacturing, and marketing and distributing pharmaceutical medicines and drugs.
    Divi's Laboratories is categorized under the Pharmaceutical and Health care sector and Pharmaceutical Industry. Healthcare sectors consist of firms involved in the medical space. It is one of the multiple sectors that comprise a range of businesses, including ones that offer medical services directly, or to those that work to develop, create and market medical equipment and medicines. It also includes the other services that provide medical insurance and other related products, and many more.
    The stocks of health care companies mostly have mixed performance. It is due to the inherent challenges to the industry each year, regulatory uncertainties, fiscal policy concerns, and more.
    Divi’s Laboratories, Competitors and Sector Peers:
    Abbott India Ltd. ABBIND
    Alembic Ltd. ALELTD
    Alembic Pharmaceuticals Ltd. ALEPHA
    Alkem Laboratories Ltd. ALKLAB
    Alpa Laboratories Ltd. ALPLAB
    Ambalal Sarabhai Enterprises Ltd. AMBSAR
    AstraZeneca Pharma India Ltd. ASTZEN
    Bafna Pharmaceuticals Ltd. BAFPHA
    Bajaj Healthcare Ltd. BAJHEA
    Biocon Ltd. BIOLTD
    Cian Healthcare Ltd.
    Cipla Ltd. CIPLTD
    Concord Drugs Ltd. CONDRU
    Dishman Pharmaceuticals & Chemicals Ltd.[Merged] DISPHA
    Divi's Laboratories Ltd. DIVIL
    Dr. Reddy's Laboratories Ltd. DR
    GlaxoSmithKline Pharmaceuticals Ltd. GLAPHA
    Glenmark Pharmaceuticals Ltd. GLEPHL
    IOL Chemicals and Pharmaceuticals Ltd. IOLCHE
    Lincoln Pharmaceuticals Ltd. LINPHA
    Lupin Ltd. LUPLTD
    Madhuveer Com 18 Network Ltd. TOHPHA
    Mahavir Advanced Remedies Ltd. INDAME
    Makers Laboratories Ltd. MAKLAB
    Natco Pharma Ltd. NATPHA
    Natural Capsules Ltd. NATCAP
    Ranbaxy Laboratories Ltd. RANLAB
    Sanofi India Ltd. AVEPHA
    Sharon Bio-Medicine Ltd. SHAPHA
    Sun Pharmaceutical Industries Ltd. SUN28
    Zenith Healthcare Ltd. ZENHEA
    Zyden Gentec Ltd. ZYDGEN
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and FrontPage will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein.

PrivacyTerms
FrontPage © 2020